22 July 2010 08:54 [Source: ICIS news]
SINGAPORE (ICIS news)--Switzerland-based chemicals and drugs maker Lonza said on Thursday its first-half net profit jumped 14.4% year on year to Swiss francs (Swfr) 135m ($129m, €101m), largely due to the strong performance of its life science ingredients business.
Details of its second-quarter results were not provided.
Lonza said its January-to-June 2010 earnings before interest, taxes, depreciation and amortisation (EBITDA) margins rose to 23.8% from 22.6% in the same period last year despite a 2.1% slippage in overall revenue to Swfr1.3bn.
The life sciences ingredients division had a 17.4% jump in operating profit to Swfr81m as sales improved 5.9% to Swfr536m, but this was offset by weaker revenue turnout at Lonza's other business divisions.
Its custom manufacturing business had a 6.8% year-on-year decline in first-half sales to Swfr658m, while revenue at its bioscience division fell 9.4% to Swfr106m, the company said.
“Lonza’s life-science strategy will continue to deliver long-term growth through an increased project pipeline, new signed contracts and an intact outsourcing trend, and investments in plants and technologies,” Lonza said.
($1 = Swfr1.05/€1 = Swfr1.34)
To discuss issues facing the chemical industry go to ICIS connect
For the latest chemical news, data and analysis that directly impacts your business sign up for a free trial to ICIS news - the breaking online news service for the global chemical industry.
Get the facts and analysis behind the headlines from our market leading weekly magazine: sign up to a free trial to ICIS Chemical Business.
|ICIS news FREE TRIAL|
|Get access to breaking chemical news as it happens.|
|ICIS Global Petrochemical Index (IPEX)|
|ICIS Global Petrochemical Index (IPEX). Download the free tabular data and a chart of the historical index|
Asian Chemical Connections